Skip to main content
. Author manuscript; available in PMC: 2017 Nov 15.
Published in final edited form as: Adv Drug Deliv Rev. 2016 Apr 29;106(Pt A):116–131. doi: 10.1016/j.addr.2016.04.020

Figure 3.

Figure 3

HDL-based nanoparticle active for PET, NIRF and photodynamic therapy. A) Schematic depiction of the HDL-based nanoparticle. B) Negative stain TEM characterization of the nanoparticles (scale bars are 100 and 20 nm in the larger view and inset, respectively). C) Analysis of photodynamic therapy effects on glioma tumors (PLP is the term for the nanoparticle). D) PET imaging of prostate cancer. E) Fluorescence molecular tomography of prostate cancer. F) Interoperative imaging aiding prostate cancer resection i) before and ii) after resection. Figure reproduced with permission from reference [120].